Core Insights - The company is advancing its detalimogene program for non-muscle invasive bladder cancer (NMIBC) with recent protocol changes and regulatory interactions aimed at improving clinical outcomes [4][5][6] Regulatory and Clinical Updates - The company has received RMAT and CDRP designations, which facilitate more frequent dialogue with the FDA and support for manufacturing readiness [5][13] - A shift in the primary endpoint from complete response (CR) at six months to CR at any time was made following FDA feedback, with interim data showing a CR rate "in the 60s" in a pivotal cohort of approximately 125 patients [6][10][11] - Management noted that protocol amendments, including T1 re-resection, TA reinduction, and requiring biopsy confirmation, contributed to improved response rates [2][3][6] Trial Design and Execution - The NMIBC trial protocol modifications are intended to align more closely with standard urologist practices, enhancing the relevance of the trial outcomes [3][6] - The pivotal cohort has exceeded enrollment objectives, making it the largest program in the NMIBC space, while other cohorts remain ongoing but are of lower priority [9] Commercial Strategy - The company is targeting community urologists, who represent over 80% of the urology market, emphasizing the importance of efficacy, tolerability, and ease of use in their product [14][16] - Detalimogene is positioned as a non-viral gene therapy that can be stored easily and administered without specialized nursing, which could streamline practice workflows [15][16] - The company anticipates a buy-and-bill model will be attractive to urology practices, with pricing flexibility expected due to its manufacturing approach [17][18] Financial Outlook - The company has a cash runway extending into the second half of 2028 and is anticipating potential approval for its product in 2027 [5][18]